【摘要】 目的探讨依达拉奉对急性重型颅脑损伤的疗效及安全性。方法79例急性重型颅脑损伤患者随机分为两组,对照组39例,给予常规治疗,依达拉奉治疗组40例,在常规治疗的基础上24h内给予依达拉奉注射液30mg加入0.9%氯化钠溶液250mL中静脉滴注,每天2次,连用14d。记录两组患者治疗前及治疗后14d的格拉斯哥昏迷评分(GCS)、脑水肿程度及治疗后3个月的格拉斯哥预后量表(GOS)评分。结果两组患者治疗前后GCS评分、脑水肿程度及3个月的GOS评分间差异均有统计学意义(P<0.05)。结论早期应用依达拉奉治疗急性重型颅脑损伤可以减轻脑水肿,促进脑神经功能的恢复,降低病残率,且不良反应小,安全性高。更多还原

【Abstract】 Objective To explore the curative effect and safety of treating acute and severe craniocerebral injury patients with Edaravone injection.Methods 79 cases of acute and severe craniocerebral injury patients were randomly divided into two groups.Of which,39 cases were given routine therapy,they were assigned into control group.40 cases,besides the routine therapy,were given Edaravone injection,30mg added in physiological saline 250ml,iv gtt,two times per day,they were assigned into Edaravone group.We recorded the Glasgow Coma Scale(GCS)before and after treatment,we also recorded the Glasgow Outcome Scale(GOS)after three months therapy.The extent of the brain edema was also recorded.ResultsThere are obvious differences in the GCS,the extent of brain edema,and the GOS between the two groups(P<0.05).Conclusions Using Edaravone to treat the acute and severe craniocerebral injury patients can lessen the brain edema,promote the recovery of the nerve function and lower the morbidity with a little adverse reaction and a high security.更多还原